Baseline immune phenotypes and CD4+ T lymphocyte responses to antiretroviral therapy in younger versus older HIV-infected individuals

Journal of Clinical Immunology

Volumn 31, Issue 5, 2011, Pages 873-881

  Hoffman, Risa M ^a   Jamieson, Beth D ^a   Bosch, Ronald J ^b   Currier, Judith ^a   Kitchen, Christina M R ^c   Schmid, Ingrid ^a   Zhu, Yuda ^c   Bennett, Kara ^b   Mitsuyasu, Ronald ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

aging; antiretroviral therapy. immune senescence; HIV AIDS; immune risk phenotype

Indexed keywords

ANTIRETROVIRUS AGENT; CD28 ANTIGEN; CD45RA ANTIGEN; CD56 ANTIGEN; CD57 ANTIGEN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGE DISTRIBUTION; AGING; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOPHENOTYPING; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENESCENCE; T LYMPHOCYTE SUBPOPULATION;

ADULT; AGE FACTORS; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOMARKERS, PHARMACOLOGICAL; CD4-POSITIVE T-LYMPHOCYTES; CELL COUNT; CELL SEPARATION; FEMALE; FLOW CYTOMETRY; HIV; HIV INFECTIONS; HUMANS; IMMUNITY, CELLULAR; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VIRUS REPLICATION;

EID: 80755163054     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-011-9550-6     Document Type: Article

References (37)

1. Grabar S, Kousignian I, Sobel A, et al. Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS. 2004;18:2029-38.
2. Cohen Stuart J, Hamann D, Borleffs J, et al. Reconstitution of naive T cells during antiretroviral treatment of HIV-infected adults is dependent on age. AIDS. 2002;16:2263-6. (Pubitemid 35449011)
3. Lederman MM, McKinnis R, Kelleher D, et al. Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase. AIDS. 2000;14:2635-42. (Pubitemid 32118716)
4. Gutierrez F, Padilla S, Masia M, et al. Clinical outcome of HIVinfected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort. PLoS One. 2006;1:e89.
5. Bonnet F, Thiebaut R, Chene G, et al. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002. HIV Med. 2005;6:198-205. (Pubitemid 40740337)
6. Chene G, Sterne JA, May M, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet. 2003;362:679-86.
7. Deeks SG. Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med. 2009;17:118-23.
8. Fagnoni FF, Vescovini R, Passeri G, et al. Shortage of circulating naive CD8(+) T cells provides new insights on immunodeficiency in aging. Blood. 2000;95:2860-8. (Pubitemid 30235896)
9. Franceschi C, Bonafe M, Valensin S, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:244-54. (Pubitemid 30462008)
10. Hadrup SR, Strindhall J, Kollgaard T, et al. Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly. J Immunol. 2006;76:2645-53. (Pubitemid 43201717)
11. Olsson J, Wikby A, Johansson B, Lofgren S, Nilsson BO, Ferguson FG. Age-related change in peripheral blood Tlymphocyte subpopulations and cytomegalovirus infection in the very old: the Swedish longitudinal OCTO immune study. Mech Ageing Dev. 2000;121:187-201. (Pubitemid 32115413)
12. Wikby A, Nilsson BO, Forsey R, et al. The immune risk phenotype is associated with IL-6 in the terminal decline stage: findings from the Swedish NONA immune longitudinal study of very late life functioning. Mech Ageing Dev. 2006;127:695-704. (Pubitemid 43949280)
13. Wikby A, Johansson B, Olsson J, Lofgren S, Nilsson BO, Ferguson F. Expansions of peripheral blood CD8 T-lymphocyte subpopulations and an association with cytomegalovirus seropositivity in the elderly: the Swedish NONA immune study. Exp Gerontol. 2002;37:445-53. (Pubitemid 34073563)
14. Ferguson FG, Wikby A, Maxson P, Olsson J, Johansson B. Immune parameters in a longitudinal study of a very old population of Swedish people: a comparison between survivors and nonsurvivors. J Gerontol A Biol Sci Med Sci. 1995;50:B378-82.
15. Huppert FA, Pinto EM, Morgan K, Brayne C. Survival in a population sample is predicted by proportions of lymphocyte subsets. Mech Ageing Dev. 2003;124:449-51. (Pubitemid 36519207)
16. Wikby A, Maxson P, Olsson J, Johansson B, Ferguson FG. Changes in CD8 and CD4 lymphocyte subsets. Tcell proliferation responses and non-survival in the very old: the Swedish longitudinal OCTO-immune study. Mech Ageing Dev. 1998;102:187-98. (Pubitemid 28353538)
17. Strindhall J, Nilsson BO, Lofgren S, et al. No Immune Risk Profile among individuals who reach 100 years of age: findings from the Swedish NONA immune longitudinal study. Exp Gerontol. 2007;42:753-61. (Pubitemid 47058867)
18. Choremi-Papadopoulou H, Viglis V, Gargalianos P, Kordossis T, Iniotaki-Theodoraki A, Kosmidis J. Downregulation of CD28 surface antigen on CD4+ and CD8+ T lymphocytes during HIV-1 infection. J Acquir Immune Defic Syndr. 1994;7:245-53.
19. Gamberg J, Pardoe I, Bowmer MI, Howley C, Grant M. Lack of CD28 expression on HIV-specific cytotoxic T lymphocytes is associated with disease progression. Immunol Cell Biol. 2004;82:38-46. (Pubitemid 38388718)
20. Ladell K, Hellerstein MK, Cesar D, Busch R, Boban D, McCune JM. Central memory CD8+ T cells appear to have a shorter lifespan and reduced abundance as a function of HIV disease progression. J Immunol. 2008;180:7907-18.
21. Cao W, Jamieson BD, Hultin LE, Hultin PM, Effros RB, Detels R. Premature aging of T cells is associated with faster HIV-1 disease progression. J Acquir Immune Defic Syndr. 2009;50:137-47.
22. Schacker TW, Bosch RJ, Bennett K, et al. Measurement of naive CD4 cells reliably predicts potential for immune reconstitution in HIV. J Acquir Immune Defic Syndr. 2010;54:59-62.
23. Mildvan D, Bosch RJ, Kim RS, et al. Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response. J Infect Dis. 2004;189:1811-20. (Pubitemid 38657217)
24. Notermans DW, Pakker NG, Hamann D, et al. Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1- infected adults. J Infect Dis. 1999;180:1050-6. (Pubitemid 30070186)
25. Kalayjian RC, Landay A, Pollard RB, et al. Age-related immune dysfunction in health and in human immunodeficiency virus (HIV) disease: association of age and HIV infection with naive CD8+ cell depletion, reduced expression of CD28 on CD8+ cells, and reduced thymic volumes. J Infect Dis. 2003;187:1924-33. (Pubitemid 36724491)
26. Papagno L, Spina CA, Marchant A, et al. Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol. 2004;2:E20.
27. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358:2095-106. (Pubitemid 351679596)
28. Wikby A, Ferguson F, Forsey R, et al. An immune risk phenotype, cognitive impairment, and survival in very late life: impact of allostatic load in Swedish octogenarian and nonagenarian humans. J Gerontol A Biol Sci Med Sci. 2005;60:556-65. (Pubitemid 40847916)
29. Nilsson BO, Ernerudh J, Johansson B, et al. Morbidity does not influence the T-cell immune risk phenotype in the elderly: findings in the Swedish NONA Immune Study using sample selection protocols. Mech Ageing Dev. 2003;124:469-76. (Pubitemid 36514902)
30. French MA, King MS, Tschampa JM, da Silva BA, Landay AL. Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4 + T cells. J Infect Dis. 2009;200:1212-5.
31. Stone SF, Price P, French MA. Dysregulation of CD28 and CTLA- 4 expression by CD4 T cells from previously immunodeficient HIV-infected patients with sustained virological responses to highly active antiretroviral therapy. HIV Med. 2005;6:278-83. (Pubitemid 41025293)
32. Effros RB, Allsopp R, Chiu CP, et al. Shortened telomeres in the expanded CD28-CD8+ cell subset in HIV disease implicate replicative senescence in HIV pathogenesis. AIDS. 1996;10: F17-22. (Pubitemid 26229506)
33. Monteiro J, Batliwalla F, Ostrer H, Gregersen PK. Shortened telomeres in clonally expanded CD28-CD8+ T cells imply a replicative history that is distinct from their CD28+CD8+ counterparts. J Immunol. 1996;156:3587-90. (Pubitemid 26137643)
34. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV- 1-specific CD4+ T cell responses associated with control of viremia. Science. 1997;278:1447-50. (Pubitemid 27509814)
35. Migueles SA, Laborico AC, Shupert WL, et al. HIV-specific CD8 + T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol. 2002;3:1061-8. (Pubitemid 35363659)
36. Nobile M, Correa R, Borghans JA, et al. De novo T-cell generation in patients at different ages and stages of HIV-1 disease. Blood. 2004;104:470-7. (Pubitemid 38900030)
37. Yang OO, Ferbas JJ, Hausner MA, et al. Effects of HIV-1 infection on lymphocyte phenotypes in blood versus lymph nodes. J Acquir Immune Defic Syndr. 2005;39:507-18. (Pubitemid 41098463)